IGM Biosciences announced they are halting the development of two investigational drugs for autoimmune and inflammatory diseases, imvotamab (an IgM-based CD20 X CD3 bispecific antibody T cell engager) and IGM-2644 (an IgM-based CD38 X CD3 bispecific antibodyT cell engager).
Interim data from the Phase 1b studies of imvotamab for people with rheumatoid arthritis and systemic lupus erythematosus (SLE) show that the depth and consistency of B cell depletion did not meet the criteria for success. Additionally, IGM-2644 is being terminated as the company reevaluates their strategic initiatives.
When a potential treatment is discontinued, clinical trials use carefully established measures to evaluate its effectiveness. If the treatment fails to meet these criteria, it is concluded that it would not provide sufficient benefit to patients. Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about medications used to treat lupus.
This post was originally published on this site